Targeted removal of PML-RARα protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia

被引:33
作者
Jing, YK [1 ]
Xia, LJ [1 ]
Waxman, S [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Div Med Oncol, Dept Med, New York, NY 10029 USA
关键词
D O I
10.1182/blood.V100.3.1008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
All-trans retinoic acid (tRA)-induced differentiation in NB4 cells, a cell line derived from an acute promyelocytic leukemia patient with t(15;17) translocation,, is markedly facilitated by sodium butyrate (NaB), a histone deacetylase inhibitor (HDACI), or by hexamethylene bisacetamide (HMBA), a non-HDACI tRA-differentiation inducer, as determined by nitroblue tetrazolium reduction. The tRA-induced expression of RIG-G, Bfl-1/A1, and p21(waf1) and, to a lesser extent, of CCAAT/enhancer binding protein-E (C/EBPepsilon) are also enhanced by such combined treatments. Both responses are associated with a facilitated diminution of the leukemogenic PML-RARalpha protein and retained DeltaPML-RARalpha, a cleavage product. Treatment with tRA in tRA differentiation-resistant NB4 subclones R4 and MR-2 does not result in PML-RARalpha diminution and the tested gene expressions. Moreover, the addition of HMBA or NaB with tRA results in only minimal increase of differentiation in the tRA differentiation-resistant subclones. The increases in acetylated histone H3 (AcH3) and AcH4 in NaB-treated NB4, R4, and MR-2 cells are similar and do not correlate with the extent of differentiation induction when NaB and HMBA are given in combination with tRA. Arsenic trioxide (As2O3) treatment results in the total degradation of PML-RARalpha without increasing AcH3 or AcH4 or inducing differentiation in R4 cells. As2O3 in combination with tRA induces gene (Bfl-1/A1 and C/EBPepsilon) expression and partial differentiation. Both NaB and HMBA addition to As2O3-Plus-tRA-treated R4 cells further enhances differentiation. These results suggest that elimination of the dominant negative PML-RARa. protein is required prior to inhibition of histone deacetylase to fully overcome tRA-differentiation resistance in APL cells. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:1008 / 1013
页数:6
相关论文
共 53 条
[1]  
BREITMAN TR, 1990, CANCER RES, V50, P6268
[2]   RETINOIC ACID IS REQUIRED FOR AND POTENTIATES DIFFERENTIATION OF ACUTE PROMYELOCYTIC LEUKEMIA-CELLS BY NONRETINOID AGENTS [J].
CHEN, A ;
LICHT, JD ;
WU, Y ;
HELLINGER, N ;
SCHER, W ;
WAXMAN, S .
BLOOD, 1994, 84 (07) :2122-2129
[3]  
Chen GQ, 1996, BLOOD, V88, P1052
[4]   Modulation of mRNA expression of a novel human myeloid-selective CCAAT/Enhancer binding protein gene (C/EBP epsilon) [J].
Chih, DY ;
Chumakov, AM ;
Park, DJ ;
Silla, AG ;
Koeffler, HP .
BLOOD, 1997, 90 (08) :2987-2994
[5]   Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor [J].
Chumakov, AM ;
Grillier, I ;
Chumakova, E ;
Chih, D ;
Slater, J ;
Koeffler, HP .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (03) :1375-1386
[6]   Acute promyelocytic leukemia: Relieving repression induces remission [J].
Collins, SJ .
BLOOD, 1998, 91 (08) :2631-2633
[7]   Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system [J].
Dai, J ;
Weinberg, RS ;
Waxman, S ;
Jing, YK .
BLOOD, 1999, 93 (01) :268-277
[8]   ALL-TRANS-RETINOIC ACID AS A DIFFERENTIATING AGENT IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA [J].
DEGOS, L ;
DOMBRET, H ;
CHOMIENNE, C ;
DANIEL, MT ;
MICLEA, JM ;
CHASTANG, C ;
CASTAIGNE, S ;
FENAUX, P .
BLOOD, 1995, 85 (10) :2643-2653
[9]  
DELVA L, 1993, BLOOD, V82, P2175
[10]   Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy [J].
Ding, W ;
Li, YP ;
Nobile, LM ;
Grills, G ;
Carrera, I ;
Paietta, E ;
Tallman, MS ;
Wiernik, PH ;
Gallagher, RE .
BLOOD, 1998, 92 (04) :1172-1183